Ixekizumab (Taltz®)

Assessment Status Rapid Review Complete
Drug Ixekizumab
Brand Taltz®
Indication For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 28/06/2016
Rapid review completed 26/07/2016
Rapid review outcome Full Pharmacoeconomic Assessment Recommended at the submitted price

September 2016

The HSE has approved reimbursement following confidential price negotiations.